EATG » News

14 Patient Organisations Call for Meaningful Involvement in European Cooperation on Health Technology Assessment (HTA)

Today, 14 European patient organisations & federations have launched a statement calling on European institutions to adopt appropriate measures to fully incorporate meaningful involvement of patients in EU cooperation on…

The EATG publishes its position paper on drugs policy

Today, on the occasion of the joint meeting of the EU Civil Society Forum on HIV, Hepatitis and TB and the EU Civil Society Forum on Drugs, the European AIDS…

The EATG in the Civil Society Fora joint meetings (Brussels 6-8 November)

From 6-8 November, the EATG will be actively engaged in developing joint advocacy, sharing with and learning from civil society partners across Europe within the EU Civil Society Forum  on…

HIV Drug Therapy 2018 Congress – Quality of Life Across Different Age Groups of People Living with HIV: A Community Perspective

The European AIDS Treatment Group had the opportunity to co-organise and co-chair the ‘Quality of Life Across Different Age Groups of PLHIV: A Community Perspective’ session during this year's HIV Drug Therapy…

STEPS V: HIV CURE COMMUNITY WORKSHOP IN GLASGOW

STEPS, a community initiative to design the pathway to a long-term remission of HIV infection, has reached its 5th edition in Glasgow. This year the theme of the meeting that was held…

HIV Outcomes meeting: Improving long-term health and well-being of people living with HIV (Brussels – 27 November 2018)

One year after the launch of policy recommendations in the European Parliament, the HIV Outcomes initiative returns with an event to launch a "virtual good practice clinic" on chronic HIV…

Join the EATG at the 2018 HIV Drug Therapy Congress in Glasgow

The European AIDS Treatment Group is present at the 2018 HIV Drug Therapy Congress in Glasgow, from the 28th to the 31st of October. As with the previous versions of…

Call for applications: Continuous Patient Education (CoPE) Special call about Living & Ageing with HIV (Quality of Life)

We are pleased to announce that a call for applications for CoPE is now open. Please find below detailed information on how to apply for this grant. The submission deadline…

HIV Travel: The Global Database on HIV-specific Travel and Residence restrictions is updated

The Global Database on HIV-specific Travel & Residence Restrictions, a useful online tool regarding the cross-border mobility of people living with HIV/AIDS, was recently updated. This is a joint collaboration…

M-Care 2018: Sharing the outcomes of the migrant advocates training programme

Today, Africa Advocacy Foundation (AAF) and the European AIDS Treatment Group (EATG) are launching the M-Care 2018 training programme report. Together with the report we are also launching a set of video…

The EU Civil Society Forum on HIV/AIDS, TB and viral hepatitis reacts to the relevant Commission Staff Working Document

GASTEIN - On 4 October -on the occasion of the European Health Forum discussion on Reaching the SDG targets on Health by 2030 - Actions needed to end AIDS & TB…

#JusticeForZak: sign the petition, join the campaign

On Friday 21 September, Zak Kostopoulos, died as a consequence of brutal beatings in Athens Greece. We call all relevant Greek authorities for a swift, thorough, independent and impartial investigation into…

We call on the authorities to ensure that justice for Zak Kostopoulos is done

On Friday 21 September, Zak Kostopoulos, died as a consequence of brutal beatings in Athens Greece. Zak was an HIV+, sex positive, queer, human rights’ activist and defender, also raising…

EATG General Assembly 2018 (Vilnius, 27-30 September)

The European AIDS Treatment Group is holding its annual General Assembly in Vilnius, Lithuania over the next four days. More than 75 members and the staff of EATG are gathering…

The Value of Health: Improving Outcomes final report was launched

Today, the The Value of Health: Improving Outcomes multi-stakeholder initiative launched its final report at the European Parliament. European AIDS Treatment Group's chair, Nikos Dedes, highlighted the critical importance of…

The European AIDS Treatment Group is looking for a Financial Assistant

Type of contract: Half-time, temporary position with possibility for extension Location: Brussels, Belgium Reporting to: Executive Director Start date: As soon as possible The European AIDS Treatment Group is looking…

The European AIDS Treatment Group is looking for an Executive Director

Type of contract: Full-time, permanent contract Location: Brussels, Belgium Reporting to: Board of Directors Start date: As soon as possible in the range of October-December 2018 The European AIDS Treatment…

2nd Hep-C Community Summit: We are more than just patients

The European AIDS Treatment Group participates in the 2nd Hep-C Community Summit that takes place on the 18th of September in Lisbon. Organised by Correlation European Harm Reduction Network, the summit will…

Webinar: Patient Engagement on Medicines Research & Development

Join us for a webinar about patient engagement in the process of research and development of medicines on Thursday, September 6 from 18:00 to 19:15 CET.   Four European patient…

Open letter: UN General Assembly High Level Meeting on the fight against Tuberculosis

Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter: 'As negotiations on the final declaration are now being…

HIV and TB treatment at risk as countries gradually lose Global Fund support

-- Low- and middle-income countries receive donor support for HIV and TB drugs from the Global Fund, but are gradually losing this support -- Global Fund policies on countries that…

HIV i-Base, HTB: HIVR4P and Glasgow conferences: first reports

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. This issue of HTB includes the first reports from the recent HIV Treatment for Prevention (HIVR4P) and Glasgow…

Viral load in semen rapidly rebounds to infectious levels during HIV treatment breaks

Viral load rebounds rapidly in semen to potentially infectious levels following interruption of combination antiretroviral therapy (cART), according to French research published in AIDS. Increases in viral load in both…

Removable PrEP implant produces high drug levels in rabbits; further studies planned

A small removable plastic implant resembling a tiny piece of dry spaghetti is capable of delivering sustained levels of the drug tenofovir, researchers told last month’s HIV Research for Prevention…

Screening for hepatitis B and hepatitis C: benefit unclear due to a lack of suitable studies

New research aims to help improve uptake of hepatitis C testing

New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the Hepatitis C Virus (HCV). HCV infects the liver. If left untreated, it can cause…

In older hep B patients, carcinoma surveillance is advised

SAN FRANCISCO — Surveillance for hepatocellular carcinoma (HCC) should continue in patients older than 50 years, even after they have undergone 5 years of therapy for chronic hepatitis B, according to…

Hepatitis C-infected organs deemed safe for transplant

SAN FRANCISCO — Direct-acting antiviral medications can make the transplantation of organs infected with hepatitis C safe for recipients who do not have the virus, new research shows. This finding…

DAA treatment and hepatic fibrosis improvement in HCV: What’s the link?

According to the results of a prospective cohort study, 57% of patients with hepatitis C virus (HCV) infection who achieved sustained virologic response (SVR) showed no improvement in hepatic fibrosis.…

Source:
MPR
Read more...

Norah Terrault, MPH, MD: Managing DAA Failures When Treating Hepatitis C Virus Infections

Patient nonadherence to treatment is an ongoing issue that physicians from all specialties face. It is particularly prevalent among patients who are infected with hepatitis C virus. Gaps in treatment…

Research reveals details of how HIV becomes infectious

HIV, the virus that causes AIDS, has been studied extensively ever since the AIDS epidemic was officially recognized by health professionals in the early 1980s. During that time, research has…

NIH scientists illuminate causes of hepatitis B virus-associated acute liver failure

National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF) — a rare condition that can turn fatal within days without liver…

AbbVie’s MAVYRET shows high virologic cure rates in treatment-naïve hepatitis C patients with compensated cirrhosis

-- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ (glecaprevir/pibrentasvir) in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)…

PROUD qualitative findings: PrEP’s impact on sexual behaviour

Qualitative data from the PROUD study revealed that pre-exposure prophylaxis (PrEP) is an important added prevention tool to strategies already in place for men in England having frequent condomless sex,…

Daily alcohol use may drive chronic pain in adults with HIV

Daily alcohol use was found to have a reciprocal relationship with greater daily pain in older adults with HIV, according to a study published in Alcohol. Researchers conducted this exploratory study to evaluate…

Sofosbuvir/ledipasvir cures most young children with hepatitis C

Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented…

Do patients with chronic liver disease face higher DILI risk?

Research suggests a link of which drug developers should be aware, expert says SAN FRANCISCO -- Individuals with certain types of chronic liver disease may be particularly susceptible to drug-induced…

Aspirin use associated with lower risk of liver cancer

Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at…

EMA’s Brexit plans ensure Agency’s focus on medicines evaluation and supervision

A report on EMA’s 24 September 2018 meeting with industry stakeholders to discuss the UK’s withdrawal from the European Union and the impact on the operation of the centralised procedure…

Source:
EMA
Read more...

MPP signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

Important collaboration will ensure affordable hepatitis C treatment options in low- and middle-income countries. San Francisco, 12 November 2018 – The Medicines Patent Pool (MPP) has today announced a new,…